NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells (Q30982341)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20439987%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

title

NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20439987%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20439987%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Lukáš Trantírek

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20439987%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Vítězslav Bryja

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20439987%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

7

Anie Aklian

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20439987%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

3

Jirina Prochazkova

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20439987%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

6

Zhufeng Ouyang

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20439987%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

2

Shunichi Murakami

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20439987%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

10

Alois Kozubik

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20439987%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

author name string

Katarina Chlebova

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20439987%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Jiri Smutny

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20439987%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

William R Wilcox

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20439987%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

language of work or name

English

0 references

publication date

3 May 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20439987%20AND%20SRC:MED&resulttype=core&format=json

Journal of Biological Chemistry

1 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20439987%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

volume

285

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20439987%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

issue

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20439987%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

page(s)

20644-20653

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20439987%20AND%20SRC:MED&resulttype=core&format=json

Activating mutations in FGFR3 and HRAS reveal a shared genetic origin for congenital disorders and testicular tumors

1 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2898326

Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2898326

FGFR3 mutations in prostate cancer: association with low-grade tumors.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2898326

Nordihydroguaiaretic acid inhibits an activated fibroblast growth factor receptor 3 mutant and blocks downstream signaling in multiple myeloma cells

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2898326

Effect of PPADS on achondroplasic chondrocytes: inhibition of FGF receptor type 3 over-activity

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2898326

STAT1 and STAT3 do not participate in FGF-mediated growth arrest in chondrocytes

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2898326

Simple, mammalian cell-based assay for identification of inhibitors of the Erk MAP kinase pathway

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2898326

Bisindolylmaleimide I suppresses fibroblast growth factor-mediated activation of Erk MAP kinase in chondrocytes by preventing Shp2 association with the Frs2 and Gab1 adaptor proteins

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2898326

Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2898326

Interaction of fibroblast growth factor and C-natriuretic peptide signaling in regulation of chondrocyte proliferation and extracellular matrix homeostasis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2898326

A protein canyon in the FGF-FGF receptor dimer selects from an à la carte menu of heparan sulfate motifs

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2898326

Cell responses to FGFR3 signalling: growth, differentiation and apoptosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2898326

FGF2 inhibits proliferation and alters the cartilage-like phenotype of RCS cells

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2898326

Structure-activity relationships of analogues of NF449 confirm NF449 as the most potent and selective known P2X1 receptor antagonist

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2898326

A network of transcriptional and signaling events is activated by FGF to induce chondrocyte growth arrest and differentiation

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2898326

Fibroblast growth factor receptor-3 as a therapeutic target for Achondroplasia--genetic short limbed dwarfism

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2898326

Structural basis for activation of fibroblast growth factor signaling by sucrose octasulfate

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2898326

Nature of Interaction between basic fibroblast growth factor and the antiangiogenic drug 7,7-(carbonyl-bis[imino-N-methyl-4,2-pyrrolecarbonylimino[N-methyl-4,2-pyrrole]-carbonylimino])-bis-(1,3-naphtalene disulfonate). II. Removal of polar interacti

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2898326

Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14)

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2898326

Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2898326

Fibroblast growth factors and their inhibitors

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2898326

Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2898326

Clinical spectrum of fibroblast growth factor receptor mutations

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2898326

FGF signaling inhibits chondrocyte proliferation and regulates bone development through the STAT-1 pathway

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2898326

Solution structure of acidic fibroblast growth factor bound to 1,3, 6-naphthalenetrisulfonate: a minimal model for the anti-tumoral action of suramins and suradistas

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2898326

Gsalpha-selective G protein antagonists

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2898326

Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2898326

Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2898326

A unique point mutation in the fibroblast growth factor receptor 3 gene (FGFR3) defines a new craniosynostosis syndrome

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2898326

Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2898326

FGFR3 and PIK3CA mutations in stucco keratosis and dermatosis papulosa nigra.

21 June 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M109.083626

NF449: a subnanomolar potency antagonist at recombinant rat P2X1 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M109.083626

Antagonistic properties of the suramin analogue NF023 at heterologously expressed P2X receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M109.083626

Understanding the mechanism of the antimitogenic activity of suramin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M109.083626

The suramin analog 4,4',4'',4'''-(carbonylbis(imino-5,1,3-benzenetriylbis (carbonylimino)))tetra-kis-benzenesulfonic acid (NF110) potently blocks P2X3 receptors: subtype selectivity is determined by location of sulfonic acid groups.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M109.083626

Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2898326

Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway

25 November 2018

1 reference

12 December 2020

Antiproliferative and angiostatic activity of suramin analogues

1 reference

12 December 2020

Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis

1 reference

12 December 2020

Fibroblast growth factor inhibits chondrocytic growth through induction of p21 and subsequent inactivation of cyclin E-Cdk2

1 reference

12 December 2020

The antitumor efficacy of cytotoxic drugs is potentiated by treatment with PNU 145156E, a growth-factor-complexing molecule

1 reference

12 December 2020

The fibroblast growth factors in multiple myeloma

1 reference

12 December 2020

MIP-1alpha (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma

1 reference

12 December 2020

Identifiers

DOI

10.1074/JBC.M109.083626

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20439987%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20439987%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

1 reference